This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bays, H. Search for Related Content Social Bookmarking                         What's this?

Atherogenic dyslipidaemia in type 2 diabetes and metabolic syndrome: current and future treatment options

L-MARC Research Center, 3288 Illinois Avenue, Louisville KY 40213, USA, HBaysMD{at}aol.com

Dyslipidaemia is a major risk factor for atherosclerotic coronary heart disease, which in turn is the commonest cause of mortality in type 2 diabetes. This highlights the importance of appropriate management of diabetic dyslipidaemia. Management is typically multifactorial and includes dietary recommendations, routine physical exercise, aggressive control of other lifestyle risk factors, and for many patients drug intervention. Future drug treatments will increasingly target not only mechanisms that might improve glucose and LDL cholesterol blood levels, but also improve other facets of diabetic dyslipidaemia, atherogenesis and vascular risk.

Key Words: diabetes • dyslipidaemia • atherogenesis • peroxisome proliferator-activated receptor • PPAR.

References

• Ford ES, Giles WH, Dietz WH Prevalence of the metabolic syndrome among US adults. JAMA 2002;287:356-9.[Abstract/Free Full Text]
• Executive summary of the third report of the NCEP expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;28:2486-97.
• Haffner SM, Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.[Abstract/Free Full Text]
• Durrington P. Clinical trials of lipid-lowering medication in diabetes. Br J Diabetes Vasc Dis 2003;3:217-20.[Abstract/Free Full Text]
• Ginsberg HN, Illingworth DR Postprandial dyslipidaemia: an atherogenic disorder common in patients with diabetes mellitus. Am J Cardiol 2001; 88(6A):9H-15H.[Web of Science][Medline] [Order article via Infotrieve]
• Gotto AM Lipid management in diabetic patients: lessons from prevention trials. Am J Med 2002;112(suppl 8A):19S-26S.
• Wilson PWF. Diabetes mellitus and coronary heart disease. Endocrinol Metab Clin 2001;30:857-81.[CrossRef]
• Superko HR Lipoprotein subclasses and atherosclerosis. Front Biosc 2001;6:D355-65.[CrossRef]
• Buse JB Lipid changes associated with diabetes therapy. Practical Diabetology 2003;March:24-9.
• McPherson R. In people with no prior history of cardiovascular disease, high-density and non-high-density lipoprotein cholesterol levels are better predictors of cardiovascular disease mortality than low-density lipoprotein levels. Evid Based Cardiovasc Med 2002;6(1):19-20.[Medline] [Order article via Infotrieve]
• Austin MA, Edwards KL Small, dense low-density lipoproteins, the insulin resistance syndrome and non-insulin-dependent diabetes. Curr Opin Lipidol 1996;7:167-71.[Web of Science][Medline] [Order article via Infotrieve]
• Bays HE Existing and investigational combination drug therapy for high-density lipoprotein cholesterol. Am J Cardiol 2002;90(suppl):30K-43K.[Web of Science][Medline] [Order article via Infotrieve]
• Bays HE Ezetimibe. Expert Opin Investig Drugs 2002;11:1587-604.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Boden G. Pathogenesis of type 2 diabetes. Endocrinol Metab Clin 2001; 30:801-15.[CrossRef]
• Kashyap S., Belfort R., Pratipanawatr T. Chronic elevation in plasma free fatty acids impairs insulin secretion in non-diabetic offspring with a strong family history of type 2 diabetes mellitus. Diabetes 2002;51(suppl 2):A12.[CrossRef]
• Zhou YP, Grill V. Long-term exposure to fatty acids and ketones inhibits B-cell function in human pancreatic islets of Langerhans. J Clin Endocrinol Metab 1995;80:1584-90.[Abstract/Free Full Text]
• Kwiterovich PO Lipoprotein heterogeneity: diagnostic and therapeutic implications. Am J Cardiol 2002;90(8A):1i-10i.[Web of Science][Medline] [Order article via Infotrieve]
• Sacks FM, and the Expert Group on HDL Cholesterol. The role of highdensity lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002;90: 139-43.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Goldberg GJ Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 2001;90(suppl 5A):965-71.
• Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.[Abstract/Free Full Text]
• Camejo G., Rosengren B., Hallberg C., Wallin B. PPAR agonists vascular effects contributing to their apparent anti-atherogenic action. Presented at the 2nd International Symposium on PPARs: from basic science to clinical applications. March, 2003.
• Lund EG, Menke JG, Sparrow CP Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler Throm Vasc Biol 2003;23:1169-77.[Abstract/Free Full Text]
• Bays HE, Dujovne CA Anti-obesity drug development. Expert Opin Investig Drugs 2002;11:1189-204.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 5, 356-360 (2003)
DOI: 10.1177/14746514030030050801


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bays, H. Search for Related Content Social Bookmarking                         What's this?